BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 2208078)

  • 21. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
    Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
    Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
    Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
    Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
    Rahman A; Fumagalli A; Barbieri B; Schein PS; Casazza AM
    Cancer Chemother Pharmacol; 1986; 16(1):22-7. PubMed ID: 3940217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL; Rauth AM; Bendayan R; Wu XY
    Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of rabbits bearing advanced VX2 tumors in the mammary gland with nano-sized liposomal adriamycin administered by various routes].
    Chen JH; Li Y; Yao Q; Ling R; Wang L; Li KZ; Wang Z; Chen T
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3039-42. PubMed ID: 16324402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice.
    Bally MB; Masin D; Nayar R; Cullis PR; Mayer LD
    Cancer Chemother Pharmacol; 1994; 34(2):137-46. PubMed ID: 8194164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: liposomal carrier for enhanced drug delivery.
    Ho JA; Fan NC; Jou AF; Wu LC; Sun TP
    Talanta; 2012 Sep; 99():683-8. PubMed ID: 22967611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
    Mayer LD; Dougherty G; Harasym TO; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.
    Gabizon AA
    Cancer Res; 1992 Feb; 52(4):891-6. PubMed ID: 1737351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.
    Lee CC; Gillies ER; Fox ME; Guillaudeu SJ; Fréchet JM; Dy EE; Szoka FC
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16649-54. PubMed ID: 17075050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.
    Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC
    Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
    de Oliveira Silva J; Fernandes RS; Ramos Oda CM; Ferreira TH; Machado Botelho AF; Martins Melo M; de Miranda MC; Assis Gomes D; Dantas Cassali G; Townsend DM; Rubello D; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2019 Oct; 118():109323. PubMed ID: 31400669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
    Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
    Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
    Gokhale PC; Radhakrishnan B; Husain SR; Abernethy DR; Sacher R; Dritschilo A; Rahman A
    Br J Cancer; 1996 Jul; 74(1):43-8. PubMed ID: 8679456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.